[1]
Andreoli, M.T. et al. 2015. Feasibility and efficacy of a mass switch from ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of neovascular age-related macular degeneration. Digital Journal of Ophthalmology. 21, 3 (Sep. 2015), 29–34. DOI:https://doi.org/10.5693/djo.01.2015.04.002.